GRANDPHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2024
May 3 05:28 ET
GRANDPHARMA: Notice of availability to Registered Shareholders and Reply Form
Apr 26 10:33 ET
GRANDPHARMA: Notice of availability to Non-registered Shareholders and Reply Form
Apr 26 10:32 ET
GRANDPHARMA: ESG Report 2023
Apr 26 10:32 ET
GRANDPHARMA: Proxy form for the annual general meeting to be held on Tuesday, 4 June 2024 or any adjournment thereof
Apr 26 10:31 ET
GRANDPHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024
Apr 3 07:42 ET
GRANDPHARMA: VOLUNTARY ANNOUNCEMENT: THE GROUP INTRODUCES A GLOBAL INNOVATIVE PRODUCT FOR THE TREATMENT OF DEMODEX BLEPHARITIS AND MEIBOMIAN GLAND DISEASE WITH DEMODEX MITES
Mar 27 05:20 ET
GRANDPHARMA: Final dividend for the year ended 31 December 2023
Mar 27 05:19 ET
GRANDPHARMA: Final dividend for the year ended 31 December 2023
Mar 26 06:03 ET
GRANDPHARMA: THE GLOBAL INNOVATIVE RDC DRUG OF THE GROUP ITM-11 IS APPROVED TO CONDUCT PHASE III CLINICAL STUDY IN CHINA
Mar 24 06:13 ET
GRANDPHARMA: Final dividend for the year ended 31 December 2023
Mar 21 07:45 ET
GRANDPHARMA: Final dividend for the year ended 31 December 2023
Mar 19 18:02 ET
GRANDPHARMA: VOLUNTARY ANNOUNCEMENT: THE GROUPS GLOBAL INNOVATIVE OPHTHALMIC DRUG GPN00884 WAS APPROVED TO CONDUCT PHASE I CLINICAL STUDY IN CHINA
Mar 7 04:36 ET
GRANDPHARMA: VOLUNTARY ANNOUNCEMENT: THE NDA OF A GLOBAL INNOVATIVE HORMONE NANOSUSPENSION EYE DROPS WAS APPROVED BY THE FDA
Mar 7 04:33 ET
GRANDPHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024
Mar 4 04:30 ET
GRANDPHARMA: ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES
Feb 29 05:21 ET
GRANDPHARMA: Notification Letter to Registered Shareholders - New Arrangements on Dissemination of Corporate Communications
Feb 27 04:49 ET
GRANDPHARMA: Notification Letter and Request Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Feb 27 04:48 ET
GRANDPHARMA: VOLUNTARY ANNOUNCEMENT: THE NDA OF THE GROUPS GLOBAL INNOVATIVE PRODUCT RYALTRIS COMPOUND NASAL SPRAY SUBMITTED TO NMPA HAS BEEN ACCEPTED
Feb 8 04:05 ET
GRANDPHARMA: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2024
Feb 2 04:10 ET
No Data
No Data